Event CoverageChips in Brains, AI in Biopharma and Learnings from China: Insights from ICR Healthcare’s 14th Annual Healthcare Conference John Mercer, Head of Global Research and Managing Director of Retail Research November 18, 2026 Reasons to ReadDiscover what brain chips, AI in biopharma and China’s rise in drug innovation mean for consumer, retail and technology companies. Read this report to discover answers to these and other questions: How are brain-computer interfaces changing what is possible for patients who have lost the ability to move or speak? Why do biopharma leaders expect AI to change the economics of drug discovery, and what is already happening in practice? As AI spreads across biopharma, what will separate the companies that gain an advantage from the rest, and how are tech investors changing deals? What do GLP-1s, sleep drugs and psychedelics suggest about consumers using medicines beyond medical need, and what does this mean for retailers and brands? How has China’s role in global biopharma evolved, and what can Western companies and investors in the UK and Europe learn from it? Companies mentioned in this report include: AstraZeneca, Blackrock Neurotech, BYD, Eli Lilly, GSK, Healx, Juvenescence, Relation Therapeutics, Trogenix. Other relevant research: What Will a Retail Health Offering Look Like in the Future, and How Can AI Support That? Market Navigator: US Drugstore and Pharmacy Retailing—Solutions for Drugstores To Win Again From Prohibition to Participation: Measuring the Impact of Cannabis and Psychedelic Mushroom Legalization on Consumer Spending Already a member? Log in You are currently viewing a preview of this report. Please select an access option to view the full report. Hide Options - Show Options + Get unlimited access to all our research with one of our membership plans. View Membership Plans or Contact us to purchase this report. Contact us ✕ This document was generated for